Mycosis Fungoides Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
BOULDER, Colo., Dec. 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its Phase 1... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 4, 2018 Category: Pharmaceuticals Source Type: clinical trials

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides
Condition: Cutaneous T-Cell Lymphoma/Mycosis Fungoides Interventions: Drug: Cobomarsen; Drug: Vorinostat Sponsor: miRagen Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2018 Category: Research Source Type: clinical trials

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides
Condition: Cutaneous T-Cell Lymphoma/Mycosis Fungoides Interventions: Drug: Cobomarsen; Drug: Vorinostat Sponsor: miRagen Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2018 Category: Research Source Type: clinical trials